Basing on uPAR-binding fragment to design chimeric antigen receptors triggers antitumor efficacy against uPAR expressing ovarian cancer cells
Open Access
- 1 September 2019
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 117, 109173
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81302242)
- National Natural Science Foundation of China (81772772)
- Department of Science and Technology of Jilin Province (20170622008JC)
This publication has 37 references indexed in Scilit:
- Designed Ankyrin Repeat Proteins (DARPins): Binding Proteins for Research, Diagnostics, and TherapyAnnual Review of Pharmacology and Toxicology, 2015
- Tumor stroma as targets for cancer therapyPharmacology & Therapeutics, 2013
- Role of Urokinase Receptor in Tumor Progression and DevelopmentTheranostics, 2013
- Structure-Driven Design of Radionuclide Tracers for Non-Invasive Imaging of uPAR and Targeted Radiotherapy. The Tale of a Synthetic Peptide AntagonistTheranostics, 2013
- Targeting the Urokinase Plasminogen Activator Receptor Inhibits Ovarian Cancer MetastasisClinical Cancer Research, 2011
- Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen ReceptorJournal of Immunotherapy, 2009
- Cleaved Forms of the Urokinase Plasminogen Activator Receptor in Plasma Have Diagnostic Potential and Predict Postoperative Survival in Patients with Ovarian CancerClinical Cancer Research, 2008
- Mechanisms of transcoelomic metastasis in ovarian cancerThe Lancet Oncology, 2006
- Å6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: A phase I trialGynecologic Oncology, 2005
- Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules?Thrombosis and Haemostasis, 2005